Epizyme Announces First Quarter 2016 Financial Results And Provides Update On Execution Against Multi-Year Company Vision
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today reported recent business and program highlights as part of its multi-year vision and financial results for the first quarter of 2016.
“We have made significant progress in our clinical development program for tazemetostat and all four areas of our multi-year vision,” said Robert Bazemore, President and Chief Executive Officer of Epizyme.
“We have made significant progress in our clinical development program for tazemetostat and all four areas of our multi-year vision,” said Robert Bazemore, President and Chief Executive Officer of Epizyme.